Apalutamide
- Generic Name
- Apalutamide
- Brand Names
- Erleada
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15F4N5O2S
- CAS Number
- 956104-40-8
- Unique Ingredient Identifier
- 4T36H88UA7
- Background
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...
- Indication
Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- Androgen Deprivation Therapy
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT05367440
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 870
- Registration Number
- NCT05362149
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT05295927
- Locations
- 🇺🇸
GU Research Network, Omaha, Nebraska, United States
🇺🇸Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT05212857
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13779
- Registration Number
- NCT05202301
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05159245
- Locations
- 🇫🇮
Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland
🇫🇮Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital OYS Cancer Center, Oulu, Finland
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04997252
- Locations
- 🇨🇳
zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT04947254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 2
- Registration Number
- NCT04926181
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04666129
- Locations
- 🇺🇸
Clinical Research Alliance, Inc., Westbury, New York, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Alliance Urology, Greensboro, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.